Division of Sports Medicine, Department of Orthopaedic Surgery, New England Baptist Hospital, Boston, Massachusetts.
Department of Orthopaedic Surgery, Tufts University School of Medicine, Boston, Massachusetts.
JBJS Rev. 2021 Jan 19;9(1):e20.00090. doi: 10.2106/JBJS.RVW.20.00090.
»: Given the relatively high prevalence of full-thickness articular cartilage lesions, including in patients who are <40 years of age, and an inability to detect some of these lesions until the time of arthroscopy, there is value in performing a single-stage cartilage procedure such as marrow stimulation (MS).
»: While the positive outcomes of first-generation MS (namely microfracture) have been observed to drop off after 24 months in several studies, improvements have been seen when compared with preoperative conditions for lesions that are 2 to 3 cm2 in size, and MS is considered to be a procedure with technical simplicity, fairly short surgical times, and relatively low morbidity. A recent study showed that autologous chondrocyte implantation (ACI) and osteochondral allograft (OCA) transplantation remain viable treatment options for chondral defects of the knee in the setting of failed MS.
»: Basic science principles that have been elucidated in recent years include (1) the creation of vertical walls during defect preparation, (2) an increased depth of subchondral penetration, (3) a smaller awl diameter, and (4) an increased number of subchondral perforations, which are all thought to help resolve issues of access to the mesenchymal stromal cells (MSCs) and the subchondral bone structure/overgrowth issues.
»: Pioneering and evolving basic science and clinical studies have led to next-generation clinical applications, such as a hyaluronic acid-based scaffold (ongoing randomized controlled trial [RCT]), an atelocollagen-based gel (as described in a recently published RCT), a micronized allogeneic cartilage scaffold (as described in a recently completed prospective cohort study), and a biosynthetic hydrogel that is composed of polyethylene glycol (PEG) diacrylate and denatured fibrinogen (as described in an ongoing prospective study).
»: This review summarizes important points for defect preparation and the recent advances in MS techniques and identifies specific scaffolding augmentation strategies (e.g., mesenchymal augmentation and scaffold stimulation [MASS]) that have the capacity to advance cartilage regeneration in light of recent laboratory and clinical studies.
»: 鉴于全层关节软骨病变的相对高发率,包括年龄<40 岁的患者,并且在关节镜检查时才能发现其中一些病变,因此进行单阶段软骨手术(如骨髓刺激术[MS])具有一定价值。
»: 虽然第一代 MS(即微骨折)的积极结果在几项研究中观察到在 24 个月后下降,但与 2 至 3 cm2 大小的病变的术前情况相比,仍有改善,MS 被认为是一种技术简单、手术时间相对较短、发病率相对较低的手术。最近的一项研究表明,在 MS 失败的情况下,自体软骨细胞植入术(ACI)和骨软骨同种异体移植(OCA)移植仍然是膝关节软骨缺损的可行治疗选择。
»: 近年来阐明的基础科学原则包括(1)在缺陷准备过程中创建垂直壁,(2)增加软骨下穿透深度,(3)使用较小的骨钻直径,以及(4)增加软骨下穿孔数量,所有这些都被认为有助于解决骨髓间充质干细胞(MSCs)和软骨下骨结构/过度生长问题的获取问题。
»: 开创性和不断发展的基础科学和临床研究带来了下一代临床应用,例如基于透明质酸的支架(正在进行的随机对照试验[RCT])、基于去端肽胶原的凝胶(如最近发表的 RCT 所述)、微化同种异体软骨支架(如最近完成的前瞻性队列研究所述)和由聚乙二醇(PEG)二丙烯酸酯和变性纤维蛋白原组成的生物合成水凝胶(如正在进行的前瞻性研究所述)。
»: 本文综述总结了缺陷准备的要点以及 MS 技术的最新进展,并确定了特定的支架增强策略(例如,间充质增强和支架刺激[MASS]),这些策略根据最近的实验室和临床研究,有能力推进软骨再生。